On December 9, 2025, the China-US Anti-Cancer Summit was successfully held. The event was jointly organized by China Anti-Cancer Association (CACA), the US-Chinese Anti-Cancer Association (USCACA), the World Association for Integrative Oncology (WAIO), and eChinaHealth. It attracted a global audience from countries including China, the United States, Canada, Norway, Finland, Russia, Sweden, Mexico, Egypt, Bahrain, and Iran, with a total online viewership reaching 16 million.
Prof. Ying Wang, Vice President of CACA, and Prof. Li Yan, Managing Director of USCACA, co-chaired the event. The summit began with an opening speech by Prof. Daiming Fan, President of CACA. The main program featured keynote presentations from leading experts in the oncology field from both China and the United States: Prof. Youlin Qiao from Peking Union Medical College; Prof. Shun Lu, Chair of CACA Immunotherapy Committee; Prof. Lillian Siu, President of the American Association for Cancer Research (AACR); Prof. Julie Gralow, Executive Vice President and Chief Medical Officer of the American Society of Clinical Oncology (ASCO); and Prof. Christina Annunziata, Senior Vice President of the American Cancer Society (ACS).
In his opening address, Prof. Fan congratulated all parties on the successful convening of the summit and thanked AACR, ASCO, ACS, and all associations of both nations for their support. He highlighted that CACA and AACR officially signed a five-year Memorandum of Understanding during the 2025 CCHIO congress in November. He expressed hope that this summit would further solidify lasting cooperation between China and the US to jointly contribute wisdom and strength to global cancer prevention and control. Furthermore, Prof. Fan elaborated on the core concepts of "Unity for a Common Cause," "Universal Salvation," and "Holistic Follow-up Care" in integrative oncology. He emphasized that this philosophy advocates a shift in medicine from "Evidence-Based Medicine" to "Inquiry-Based Medicine" and a transformation in cancer care from traditional "anti-cancer" approaches to strategies focused on "tumor control" and "patient preservation." Finally, he noted that through events like the CCHIO congress and international summits, CACA has successfully established a high-level platform for international exchange and cooperation, putting the principles of integrative oncology into practice.
Keynote Speeches
Prof. Lillian Siu, President (2025-2026) of AACR and a Senior Medical Oncologist at Princess Margaret Cancer Centre, presented on "Progress Against Cancer in 2025." She reviewed achievements in reducing cancer mortality and expanding the survivor population in the US, while outlining future directions driven by immunotherapy, ADC drugs, and cutting-edge technologies.
Prof. Youlin Qiao from Peking Union Medical College and a member of the WHO Global Expert Group on Cervical Cancer Elimination delivered a lecture titled "Enhance Health Cooperation to Accelerate Elimination of Cervical Cancer in China." He discussed pathways and strategies for China to accelerate progress toward eliminating cervical cancer from epidemiological and global cooperation perspectives.
Prof. Julie Gralow, Executive Vice President and Chief Medical Officer of ASCO, shared insights on "Clinical Oncology Progress in the United States." She systematically presented the latest trends from an ASCO viewpoint, including annual clinical research breakthroughs, innovations in diagnosis and treatment models, and improvements in patient care.
Prof. Shun Lu, Lifetime Professor at Shanghai Chest Hospital and Chair of CACA Immunotherapy Committee, gave a lecture titled "Early Drug Development of Lung Cancer in China: Learnings from the Past and Solutions for the Future" He reviewed the history, current status, and future plans for early-stage lung cancer drug development in China, with a particular focus on the application prospects of innovative strategies like immunotherapy.
Prof. Christina Annunziata, Senior Vice President of ACS, presented a lecture called "Discovery and Creative Innovation Transforming Cancer Research and Patient Care at the American Cancer Society." She introduced a series of data-driven actions taken by ACS to advance cancer control, including establishing funding programs for cutting-edge research, promoting prevention science, and optimizing patient support systems.
Panel Discussion
During the panel discussion, Chinese and US experts held in-depth exchanges on deepening China-US cooperation in cancer control. Participants unanimously agreed that coordinating clinical trials, harmonizing data standards, and expediting regulatory reviews could significantly accelerate new drug development for the benefit of patients worldwide. Prof. Fan specifically pointed out that the frontline of cancer control needs to "move forward," advocating for the establishment of a comprehensive system covering prevention, early screening, early diagnosis, and whole-life-cycle management. He also called for integrating the strengths of Chinese and Western medicine to improve patient quality of life. Ultimately, the experts reached a key consensus: by establishing regular transnational coordination mechanisms and integrating the strengths of both sides in patient resources, scientific research capabilities, and innovative ideas, China and the United States can work together to accelerate progress against cancer for the ultimate benefit of patients globally.
The insightful presentations at this summit covered multi-dimensional perspectives ranging from basic research and clinical translation to public health policy, injecting new momentum into the global fight against cancer. In the future, CACA will continue to unite anti-cancer forces both domestically and internationally. With a more open attitude and pragmatic actions, CACA is committed to deepening its integration into the global cancer community.
